Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion

Therapeutics and Clinical Risk Management

Volumn 3, Issue 2, 2007, Pages 291-299

  Cappellini, Maria Domenica ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Deferasirox; Effective; Exjade; Transfusional iron overload

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HUMAN; INDIVIDUALIZATION; IRON CHELATION; IRON OVERLOAD; KIDNEY FAILURE; MORBIDITY; MORTALITY; NEUTROPENIA; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME;

EID: 34250003044     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2007.3.2.291     Document Type: Review

References (43)

1. al Refaie FN, Hershko C, Hoffbrand AV, et al. 1995. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol, 91:224-9.
2. Apotex. 2004. Ferriprox package insert.
3. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. 2006. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood, 107:3733-7.
4. Brittenham GM, Griffith PM, Nienhuis AW, et al. 1994. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med, 331:567-73.
5. Cabantchik ZI, Breuer W, Zanninelli G, et al. 2005. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol, 18:277-87.
6. Cappellini MD, Bejaoui M, Agaoglu L, et al. 2005. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy [abstract]. Blood, 106:2704.
7. Cappellini NO, Cohen A, Piga A, et al. 2006. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 107:3455-62.
8. Cighetti G, Duca L, Bortone L, et al. 2002. Oxidative status and malondialdehyde in beta-thalassaemia patients. Eur J Clin Invest, 32 (Suppl 1):55-60.
9. Cohen A, Masera G, Zoumbos N, et al. 2005. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade®, ICL670) [abstract]. Blood, 106:822.
10. Cunningham MJ, Macklin EA, Neufeld EJ, et al. 2004. Complications of beta-thalassemia major in North America. Blood, 104:34-9.
11. Daar S, Taher A, Pathare A, et al. 2006. Deferasirox (Exjade® ICL 670) provides 24-hour protection from labile plasma iron (LPI), in iron overloaded β-thalassaemia patients previously chelated with mono- or combination therapy [abstract]. Haematologica, 91(Suppl 1)31.
12. De Luca C, Filosa A, Grandinetti M, et al. 1999. Blood antioxidant status and urinary levels of catecholamine metabolites in beta-thalassemia. Free Radic Res, 30:453-62.
13. Eleftheriou P, Tanner M, Pennell D, et al. 2006. Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; a subgroup analysis [abstract]. Haematologica, 91(Suppl 1):999.
14. [EMEA] European Medicines Agency. 2005. Ferriprox European Public Assessment Report, Scientific Discussion. www emea eu int.
15. [Exjade PI] Novartis Pharmaceuticals Corporation. 2005. Exjade (deferasirox) Prescribing information [online]. Accessed on 20 February 2007. URL: http://www.exjade.com.
16. Forni GL, Piga A, Galanello R, et al. 2005. Growth and sexual development in pediatric patients treated over 48 weeks with ICL670, a once-daily oral iron chelator [abstract]. Ped Blood Cancer, 44:1106.
17. Galanello R, Piga A, Alberti D, et al. 2003. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol, 43:565-72.
18. Galanello R, Piga A, Forni GL, et al. 2006. Phase II clinical evaluation of deferasirox (Exjade, ICL670), a once-daily oral chelating agent, in paediatric patients with β-thalassaemia major. Haematologica, 91:1343-51.
19. Gattermann N, Cazzola M, Greenberg P, et al. 2005. The efficacy and tolerability of ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndrome (MDS) and iron overload. Leuk Res, 29(Suppl 1):S67.
20. Glickstein H, Ben El R, Shvartsman M, et al. 2005. Intracellular labile iron pools as direct targets of iron chelators. A fluorescence study of chelator action in living cells. Blood, 106:3242-50.
21. Greenberg P, Dine G, Ganser A, et al. 2005. Deferasirox (Exjade®, ICL670) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia [abstract]. Blood, 106:2694.
22. Greenberg PL, Baer MR, Bennett JM, et al. 2006. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw, 4:58-77.
23. Hershko C, Konijn AM, Nick HP, et al. 2001. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood, 97:1115-22.
24. Hoffbrand AV, Cohen A, Hershko C. 2003. Role of deferiprone in chelation therapy for transfusional iron overload. Blood, 102:17-24.
25. Ishizaka N, Saito K, Mitani H, et al. 2002. Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. Circulation, 106:1840-6.
26. Modell B, Khan M, Darlison M. 2000. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet, 355:2051-2.
27. Nick H, Acklin P, Lattmann R, et al. 2003. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem, 10:1065-76.
28. Nick H, Wong A, Acklin P, et al. 2002. ICL670A: preclinical profile. Adv Exp Med Biol, 509:185-203.
29. Nisbet-Brown F, Olivieri NF, Giardina PJ, et al. 2003. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet, 361:1597-602.
30. Olivieri NF, Nathan DG, MacMillan JH, et al. 1994. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med, 331:574-8.
31. Pennell DJ, Berdoukas V, Karagiorga M, et al. 2006. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood, 107:3738-44.
32. Piga A, Galanello R, Forni GL, et al. 2006. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 91:873-80.
33. Piga A, Galanello R, Foschini ML, et al. 2004. Once-daily treatment with the oral iron chelator ICL670 (Exjade®): Results of a Phase II study in pediatric patients with β-thalassemia major [abstract]. Blood, 104:3614.
34. Porter J, Borgna-Pignatti C, Baccarani M, et al. 2005. Iron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis [abstract]. Blood, 106:2690.
35. Porter JB, Abeysinghe RD, Marshall L, et al. 1996. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood, 88:705-13.
36. Porter JB. 2001a. Practical management of iron overload. Br J Haematol, 115:239-52.
37. Porter JB. 2001b. Deferoxamine pharmacokinetics. Semin Hematol, 38:63-8.
38. Steinhauser S, Heinz U, Bartholoma M, et al. 2004. Complex formation of ICL670 and related ligands with Fe III and Fe II. Eur J Inorg Chem, 21:4177-92.
39. Tchernia G, Vichinsky E, Jeng M, et al. 2005. The once-daily oral iron chelator ICL670 is well tolerated and effective in treating transfusional iron overload in Diamond-Blackfan anaemia patients. Haematologica, 90(Suppl 2):192.
40. Vichinsky E, Fischer R, Fung F, et al. 2005. A randomized, controlled Phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade®, ICL670) is well tolerated and reduces iron burden [abstract]. Blood, 106:313.
41. Vichinsky E, Fischer R, Pakbaz Z, et al. 2005. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): comparison between deferasirox (Exjade®, ICL670) and deferoxamine (DFO) [abstract]. Blood, 106:2334.
42. Wonke B. 2001. Clinical management of beta-thalassemia major. Semin Hematol, 38:350-9.
43. Wood JC, Otto-Duessel M, Gonzales I, et al. 2005. ICL670 removes cardiac iron in a gerbil model of iron overload [abstract]. Blood, 106:2695.